Published in Cancer Res on February 15, 2005
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol (2005) 2.74
Protease-activated receptor 2 signaling in inflammation. Semin Immunopathol (2011) 1.47
Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res (2009) 1.33
The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol (2012) 1.25
Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res (2009) 1.22
Tissue factor and cell signalling in cancer progression and thrombosis. J Thromb Haemost (2011) 1.20
Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res (2008) 1.19
Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol (2014) 1.17
Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res (2006) 1.13
Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells. Br J Cancer (2009) 1.12
Tissue factor, blood coagulation, and beyond: an overview. Int J Inflam (2011) 1.05
Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol (2006) 1.04
Human Brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma. Cancer Res (2014) 0.96
Tissue factor and cancer. Thromb Res (2012) 0.95
Activation of blood coagulation in cancer: implications for tumour progression. Biosci Rep (2013) 0.94
Tissue factor, angiogenesis and tumour progression. Breast Cancer Res (2008) 0.93
Venous thromboembolism in malignant gliomas. J Thromb Haemost (2009) 0.92
MDM2 regulates hypoxic hypoxia-inducible factor 1α stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner. J Biol Chem (2014) 0.92
Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. Proc Natl Acad Sci U S A (2014) 0.91
Holothurian glycosaminoglycan inhibits metastasis and thrombosis via targeting of nuclear factor-κB/tissue factor/Factor Xa pathway in melanoma B16F10 cells. PLoS One (2013) 0.89
Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model. J Thromb Haemost (2009) 0.89
The prothrombotic activity of cancer cells in the circulation. Blood Rev (2015) 0.88
Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma. Brain Pathol (2007) 0.87
Differential sensitivity of human glioblastoma LN18 (PTEN-positive) and A172 (PTEN-negative) cells to Taxol for apoptosis. Brain Res (2008) 0.85
Thromboembolic disease in patients with high-grade glioma. Neuro Oncol (2012) 0.85
Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia. Mediterr J Hematol Infect Dis (2011) 0.84
Brain neoplasms and coagulation-lessons from heterogeneity. Rambam Maimonides Med J (2014) 0.83
The tick-derived inhibitor Ixolaris prevents tissue factor signaling on tumor cells. J Thromb Haemost (2012) 0.81
P14ARF suppresses tumor-induced thrombosis by regulating the tissue factor pathway. Cancer Res (2014) 0.81
Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol (2016) 0.79
The pro-migratory and pro-invasive role of the procoagulant tissue factor in malignant gliomas. Cell Adh Migr (2011) 0.79
PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression. J Neurooncol (2013) 0.78
Cancer and Venous Thromboembolic Disease: A Review. Oncologist (2017) 0.78
Hypoxia regulates the expression of tissue factor pathway signaling elements in a rat glioma model. Oncol Lett (2016) 0.77
Changes in the Laboratory Data for Cancer Patients Treated with Korean-medicine-based Inpatient Care. J Pharmacopuncture (2014) 0.77
Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets. World J Clin Oncol (2014) 0.76
Potential Coagulation Factor-Driven Pro-Inflammatory Responses in Ovarian Cancer Tissues Associated with Insufficient O₂ and Plasma Supply. Int J Mol Sci (2017) 0.75
Preparation and characterization of anti-tissue factor single-chain variable fragment antibody for cancer diagnosis. Cancer Sci (2014) 0.75
Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft model. Sci Rep (2017) 0.75
Glioblastoma on a microfluidic chip: Generating pseudopalisades and enhancing aggressiveness through blood vessel obstruction events. Neuro Oncol (2017) 0.75
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Natural mutagenesis of human genomes by endogenous retrotransposons. Cell (2010) 5.50
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
An integrative approach for in silico glioma research. IEEE Trans Biomed Eng (2010) 4.55
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol (2005) 3.42
Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res (2004) 2.90
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res (2008) 2.81
Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res (2004) 2.79
Discovery of a proneurogenic, neuroprotective chemical. Cell (2010) 2.78
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol (2005) 2.74
Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol (2004) 2.71
Integrated morphologic analysis for the identification and characterization of disease subtypes. J Am Med Inform Assoc (2012) 2.68
Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg (2007) 2.43
Real-time magnetic resonance-guided stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy. Neurosurgery (2014) 2.41
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol (2011) 2.39
'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol (2006) 2.37
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res (2008) 2.30
Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. J Neurosurg (2003) 2.24
Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. Am J Clin Pathol (2005) 2.17
Pituicytoma: report of two cases and clues regarding histogenesis. Neurosurgery (2004) 2.17
Reactive retinal astrocytic tumors (so-called vasoproliferative tumors): histopathologic, immunohistochemical, and genetic studies of four cases. Am J Ophthalmol (2012) 2.12
Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest (2004) 2.03
The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One (2010) 1.86
MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology (2013) 1.77
The neuronal PAS domain protein 3 transcription factor controls FGF-mediated adult hippocampal neurogenesis in mice. Proc Natl Acad Sci U S A (2005) 1.71
Cancer susceptibility variants and the risk of adult glioma in a US case-control study. J Neurooncol (2011) 1.69
Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res (2005) 1.67
PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem (2001) 1.66
Integrative, multimodal analysis of glioblastoma using TCGA molecular data, pathology images, and clinical outcomes. IEEE Trans Biomed Eng (2011) 1.63
The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res (2008) 1.63
Machine-based morphologic analysis of glioblastoma using whole-slide pathology images uncovers clinically relevant molecular correlates. PLoS One (2013) 1.62
Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res (2002) 1.62
Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol (2004) 1.61
Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene (2005) 1.61
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res (2007) 1.60
Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell (2009) 1.60
Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am J Pathol (2004) 1.58
Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains. Gene (2002) 1.58
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
Rap1a null mice have altered myeloid cell functions suggesting distinct roles for the closely related Rap1a and 1b proteins. J Immunol (2007) 1.56
mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol (2005) 1.56
Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs (2005) 1.52
Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene (2002) 1.52
PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt activity and mediates cellular invasion. J Biol Chem (2004) 1.47
Astroblastoma: radiologic-pathologic correlation and distinction from ependymoma. AJNR Am J Neuroradiol (2002) 1.44
Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol (2007) 1.44
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol (2013) 1.43
Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res (2005) 1.42
Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology (2012) 1.41
The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc Natl Acad Sci U S A (2003) 1.40
IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Childs Nerv Syst (2010) 1.39
Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res (2009) 1.39
Protease-activated receptor-1 in human brain: localization and functional expression in astrocytes. Exp Neurol (2004) 1.36
Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells. Cancer Res (2003) 1.36
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J Immunother (2009) 1.33
Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res (2009) 1.33
Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res (2004) 1.32
Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem (2006) 1.29
Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv Anat Pathol (2002) 1.29
PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res (2003) 1.27
Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nat Commun (2013) 1.26
Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res (2011) 1.26
Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res (2004) 1.26
MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS One (2013) 1.25
The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol (2012) 1.25
Protocol for the examination of specimens from patients with tumors of the brain/spinal cord. Arch Pathol Lab Med (2008) 1.25
The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol (2003) 1.24
Brain cancer propagating cells: biology, genetics and targeted therapies. Trends Mol Med (2009) 1.23
Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res (2006) 1.23
The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma. Cancer Res (2009) 1.22
Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res (2009) 1.22
Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am J Pathol (2003) 1.21
Anaplastic meningioma versus meningeal hemangiopericytoma: immunohistochemical and genetic markers. Hum Pathol (2004) 1.21
Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res (2007) 1.20
Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res (2004) 1.19